Literature DB >> 21241799

Biliverdin reductase--a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment.

Eugenio Barone1, Fabio Di Domenico, Giovanna Cenini, Rukhsana Sultana, Chiara Cini, Paolo Preziosi, Marzia Perluigi, Cesare Mancuso, D Allan Butterfield.   

Abstract

Biliverdin reductase-A is a pleiotropic enzyme involved not only in the reduction of biliverdin-IX-alpha into bilirubin-IX-alpha, but also in the regulation of glucose metabolism and cell growth secondary to its serine/threonine/tyrosine kinase activity. Together with heme oxygenase, whose metabolic role is to degrade heme into biliverdin-IX-alpha, it forms a powerful system involved in the cell stress response during neurodegenerative disorders. In this paper, an up-regulation of the biliverdin reductase-A protein levels was found in the hippocampus of the subjects with Alzheimer disease and arguably its earliest form, mild cognitive impairment. Moreover a significant reduction in the phosphorylation of serine, threonine and tyrosine residues of biliverdin reductase-A was found, and this was paralleled by a marked reduction in its reductase activity. Interestingly, the levels of both total and phosphorylated biliverdin reductase-A were unchanged as well as its enzymatic activity in the cerebella. These results demonstrated a dichotomy between biliverdin reductase-A protein levels and activity in the hippocampus of subjects affected by Alzheimer disease and mild cognitive impairment, and this effect likely is attributable to a reduction in the phosphorylation of serine, threonine and tyrosine residues of biliverdin reductase-A. Consequently, not just the increased levels of biliverdin reductase-A, but also its changed activity and phosphorylation state, should be taken into account when considering potential biomarkers for Alzheimer disease and mild cognitive impairment.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241799      PMCID: PMC3042515          DOI: 10.1016/j.bbadis.2011.01.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  38 in total

1.  Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation.

Authors:  M Salim; B A Brown-Kipphut; M D Maines
Journal:  J Biol Chem       Date:  2001-01-17       Impact factor: 5.157

Review 2.  Mild cognitive impairment clinical trials.

Authors:  Ronald C Petersen
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

3.  Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Georgianne F Tiu; Nicole N Scheff; Marzia Perluigi; Chiara Cini; D Allan Butterfield
Journal:  Brain Res       Date:  2010-04-01       Impact factor: 3.252

4.  Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme.

Authors:  P J Pereira; S Macedo-Ribeiro; A Párraga; R Pérez-Luque; O Cunningham; K Darcy; T J Mantle; M Coll
Journal:  Nat Struct Biol       Date:  2001-03

5.  Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease.

Authors:  T Kimpara; A Takeda; T Yamaguchi; H Arai; N Okita; S Takase; H Sasaki; Y Itoyama
Journal:  Neurobiol Aging       Date:  2000 Jul-Aug       Impact factor: 4.673

6.  The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions?

Authors:  M D Maines; N Panahian
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

7.  The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease.

Authors:  Claudius Mueller; Weidong Zhou; Amy Vanmeter; Michael Heiby; Shino Magaki; Mark M Ross; Virginia Espina; Matthew Schrag; Cindy Dickson; Lance A Liotta; Wolff M Kirsch
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 9.  Heme oxygenase and its products in the nervous system.

Authors:  Cesare Mancuso
Journal:  Antioxid Redox Signal       Date:  2004-10       Impact factor: 8.401

Review 10.  Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress.

Authors:  H Fai Poon; Vittorio Calabrese; Giovanni Scapagnini; D Allan Butterfield
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-05       Impact factor: 6.053

View more
  32 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

3.  Cytochrome c peroxidase activity of heme bound amyloid β peptides.

Authors:  Manas Seal; Chandradeep Ghosh; Olivia Basu; Somdatta Ghosh Dey
Journal:  J Biol Inorg Chem       Date:  2016-06-07       Impact factor: 3.358

4.  Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues.

Authors:  Wei Song; Hillel Zukor; Adrienne Liberman; Sagi Kaduri; Zoe Arvanitakis; David A Bennett; Hyman M Schipper
Journal:  Exp Neurol       Date:  2014-01-15       Impact factor: 5.330

Review 5.  The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

Authors:  Eugenio Barone; Fabio Di Domenico; Cesare Mancuso; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2013-10-02       Impact factor: 5.996

Review 6.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

7.  NADPH oxidase 1, a novel molecular source of ROS in hippocampal neuronal death in vascular dementia.

Authors:  Dong-Hee Choi; Kyoung-Hee Lee; Ji-Hye Kim; Ju-Ha Seo; Hahn Young Kim; Chan Young Shin; Jung-Soo Han; Seol-Heui Han; Yoon-Seong Kim; Jongmin Lee
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

Review 8.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 9.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

Review 10.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.